On June 25, 2025, Cero Therapeutics Holdings, Inc. amended their securities purchase agreement to add new institutional investors and agreed to sell an additional 2,315 shares of Series D preferred stock, raising approximately $1.85 million. This follows a prior sale of 938 shares for about $750,400 on June 5, 2025.